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Lysophosphatidic acid acyltransferase activityThe patatin-like phospholipase domain containing 3 (PNPLA3, also called adiponutrin, ADPN) is a membrane-
bound protein highly expressed in the liver. The genetic variant I148M (rs738409) was found to be associated
with progression of chronic liver disease. We aimed to establish a protein puriﬁcation protocol in a yeast system
(Pichia pastoris) and to examine the human PNPLA3 enzymatic activity, substrate speciﬁcity and the I148Mmu-
tation effect. hPNPLA3 148I wild type and 148M mutant cDNA were cloned into P. pastoris expression vectors.
Yeast cells were grown in 3 L fermentors. PNPLA3 protein was puriﬁed from membrane fractions by Ni-afﬁnity
chromatography. Enzymatic activity was assessed using radiolabeled substrates. Both 148I wild type and 148M
mutant proteins are localized to the membrane. The wild type protein shows a predominant lipase activity
with mild lysophosphatidic acid acyl transferase activity (LPAAT) and the I148M mutation results in a loss of
function of both these activities. Our data show that PNPLA3 has a predominant lipase activity and I148Mmuta-
tion results in a loss of function.
© 2014 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Hepatic steatosis is deﬁned as the accumulation of triglycerides and
other fat species in the liver and can lead to steato-hepatitis, cirrhosis
and eventually to hepatocellular carcinoma. The incidence of hepatic
steatosis is increasing rapidly in line with the obesity epidemic and it
is now recognized as a major health burden worldwide. Genetic factors
are known to be involved in the development of this condition, and adomain containing 3; ADPN,
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GY, buffered glycerol-complex
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. Open access under CC BY-NC-ND licrecent genome wide association study showed that liver triglyceride
content is associated with the patatin-like phospholipase domain con-
taining 3 (PNPLA3), also called adiponutrin (ADPN), locus [1]. A cytosine
to guanine DNA substitution (rs738409)was found to encode an isoleu-
cine (I) to methionine (M) substitution at the amino acidic residue 148
of the PNPLA3 protein. This sequence variant is now the most well-
replicated genetic locus found associated with hepatic steatosis [2]
and the entire spectrum of liver disease ranging from a simple increase
in transaminase levels, to inﬂammation, ﬁbrosis, cirrhosis and ultimate-
ly hepatocellular carcinoma [3–12].
PNPLA3 is amembrane-boundprotein and is highly expressed in the
liver. It consists of 481 amino acids with a molecular mass of approxi-
mately 53 kDa. Despite a large number of studies on PNPLA3, the enzy-
matic activity of PNPLA3 and the effect of the amino acid substitution
remain controversial. Pnpla3 knockout mouse models show no speciﬁc
phenotype [13,14] while pnpla3 silencing in rats results in a reduced
liver triglyceride content [15]. Murine overexpression of the human
PNPLA3 (hPNPLA3) 148M mutant protein has been shown to promote
increased hepatic fat content, consistent with the substitution causing
a gain of function [16]. However, overexpression of the PNPLA3 148M
mutant protein in hepatic cell lines induces a reduced intracellular li-
pase activity [17,18]. Recombinant human PNPLA3 puriﬁed fromense.
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nant lipase activity and the mutation causes a loss of the enzymatic
function [19]. In comparison, PNPLA3 puriﬁed from bacterial cells
(Escherichia coli) was shown to have a predominant triglyceride syn-
thase (i.e. lysophosphatidic acid acyl transferase, LPAAT) activity with
the I148Mmutation causing a gain of this activity [20].
In this manuscript ﬁrst we aimed to establish a protocol to produce
PNPLA3 protein in Pichia pastoris [21], a yeast system allowing puriﬁca-
tion of eukaryotic membrane proteins [22]. Next, we tested the PNPLA3
protein enzymatic activity, substrate speciﬁcity and the effect of the
I148M substitution.
2. Materials and methods
2.1. Construction of recombinant PNPLA3 148I wild type and 148Mmutant
Human PNPLA3 148I wild type cDNA was cloned into the P. pastoris
expression vectors pPICZB and pPICZαA (Invitrogen) for intracellular
and secreted production, respectively (pPICZB-His6-hPNPLA3, pPICZB-
hPNPLA3-His6, and pPICZαA-hPNPLA3-His6), using commercially syn-
thesized PCR primers (Sigma). In pPICZB-His6-hPNPLA3, PNPLA3 was
cloned as a fusion with an N-terminal His6-tag using the following
primers (for all primers, the consensus sequence for improved produc-
tion is shown in bold and the restriction sites are underlined): forward
primer, EcoRI-hPNPLA3 (5′-ATA CCG GAA TTC AAA ATG CAT CAT CAT
CAT CAT CAT TAC GACGCAGAG CGCGGC TGGAGC T-3′); reverse prim-
er, XbaI-hPNPLA3 (5′-A TAC TAG TCT AGA TCA CAG ACT CTT CTC TAG
TGA AAA ACT GGG AAA GGT-3′). In pPICZB-hPNPLA3-His6, PNPLA3
was cloned as a fusion with a C-terminal His6-tag using the following
primers: forward primer, EcoRI-hPNPLA3 II (5′-ATA CCG GAA TTC AAA
ATG TAC GAC GCA GAG CGC GGC TGG AGC T-3′); reverse primer,
XbaI-hPNPLA3 II (5′-A TAC TAG TCT AGA TCA ATG ATG ATG ATG ATG
ATG CAG ACT CTT CTC TAG TGA AAA ACT GGG-3′). In pPICZαA-
hPNPLA3-His6, PNPLA3 was cloned as a fusion with the α-factor secre-
tion signal from Saccharomyces cerevisiae (~10 kDa) and a C-terminal
His6-tag using the following primers: forward primer, EcoRI-hPNPLA3
III (5′-ATA CCG GAA TTC ATG TAC GAC GCA GAG CGC GGC TGG AGC
TTG TCC-3′); reverse primer, XbaI-hPNPLA3 II. Human PNPLA3 148M
mutant cDNA was cloned as a fusion with a C-terminal His6-tag into
the pPICZB vector using as forward primer EcoRI-hPNPLA3 and reverse
primer XbaI-hPNPLA3 II, resulting in the pPICZB-hPNPLA3-I148M-His6
construct. Correct sequences were conﬁrmed by sequencing (Euroﬁns
MWG Operon).
2.2. High-zeocin screening and small-scale production of PNPLA3 148I wild
type and 148M mutant
The resulting expression vectors were linearized with PmeI
restriction enzyme (Fermentas) and transformed into the P. pastoris
wild type strain X-33 (Invitrogen) by electroporation (Invitrogen)
[23].
For each construct, 52colonies were screened for growth on Yeast
Extract Peptone Dextrose plus Sorbitol (YPDS) (Invitrogen) plates con-
taining a high concentration (2000 μg/mL) of zeocin (Invitrogen) and
analyzed after 3 days. Three of the best growing clones for each con-
struct were selected for small-scale production in shake ﬂask cultures
(25 mL), as previously described [24]. Brieﬂy, pre-cultures were
grown overnight in 5 mL buffered glycerol-complex medium (BMGY)
(Invitrogen) and protein expression was induced by incubation in buff-
ered methanol-complex medium (BMMY) (Invitrogen) for 6 h. Cells
were then harvested and resuspended in cell resuspension buffer
(CRB) plus glass beads (cell pellet: CRB:glass beads at a 1:1:1 ratio,
v/v). The cells were broken using FastPrep (FP 120, Bio 101 Savant)
and cell lysates and cytosolic and membrane fractions were obtained
after repeated rounds of centrifugation [25]. For pPICZαA-hPNPLA3-
His6, proteins in the cell culture medium were precipitated using 10%trichloroacetic acid (TCA) and washed with cold acetone. Each fraction
was subsequently analyzed by SDS-PAGE and immunoblot. P. pastoris
cells transformed with a heterologous protein known to be highly
expressed (human Aquaporin 1, hAQP1; pPICZB-hAQP1-His6) [24] or
with the empty vector were used as positive and negative controls,
respectively.
2.3. Large-scale production of PNPLA3 148I wild type and 148M mutant
To optimize protein production, P. pastoris strains producing recom-
binant PNPLA3 148I wild type (X33/pPICZB-hPNPLA3-His6) and 148M
mutant (X33/pPICZB-hPNPLA3-148M-His6) were grown at 30 °C in a
3 L fermentor (Infors HT) with an initial fermentation volume (IFV) of
1.5 L basal salt medium [26] containing 6.53 mL of PTM1 trace salts
[27]. The fermentors were inoculated with 100 mL of overnight pre-
cultures in BMGY medium, with an optical density (OD) at 600 nm of
approximately 4. After consumption of the initial glycerol contained in
the basal salt medium, cultures were fed with 250 mL of 50% glycerol
(v/v) in ultrapure water to increase biomass.
To induce the production of recombinant PNPLA3 148Iwild type and
148Mmutant, cultures were fed with 100%methanol for 50 h (250 mL
methanol was consumed for each fermentor).
To obtain membrane fractions, P. pastoris cells overproducing
PNPLA3 148I wild type and 148M mutant were resuspended in buffer
A (50 mM Tris pH 7.4, 150 mM NaCl, 0.5 mM phenylmethylsulfonyl
ﬂuoride) at a concentration of 1000 mg/mL and broken by three pas-
sages through an X-Press (AB Biox). After 30 min centrifugation at
6000 g, the supernatant containing membrane and cytosolic frac-
tions was collected. The membrane fraction was isolated from the
cleared supernatant by ultracentrifugation in a Ti45 rotor at
140,000 g for 1 h. The membrane pellet was resuspended in buffer
B (50 mM Tris pH 7.4, 150 mM NaCl, and 20% glycerol) and homog-
enized using a handheld electric homogenizer at a concentration of
approximately 300 mg/mL. The membrane fractions were analyzed
by SDS-PAGE and immunoblot.
2.4. Large-scale solubilization and puriﬁcation of PNPLA3 148I wild type
and 148M mutant
Cell membranes (4 g) were resuspended to a total membrane
concentration of 150 mg/mL in solubilization buffer (50 mM Tris–
HCl pH 7.4, 150 mM NaCl, 0.2% sodium deoxycholate, 2% FOS-
CHOLINE®-12, and 20% glycerol) and mixed by gentle agitation for
3 h at 4 °C. The solubilized membranes were centrifuged at
120,000 g for 1 h as previously described [19]. The supernatant, con-
taining solubilized proteins, was collected and mixed by gentle agi-
tation overnight at 4 °C with 3 mL of Ni–nitrilotriacetic acid (NTA)
agarose slurry (Qiagen), pre-equilibrated with 50 mL of equilibra-
tion buffer (50 mM Tris–HCl pH 7.4, 150 mM NaCl, 0.1% sodium
deoxycholate, 0.1% FOS-CHOLINE®-12, and 20% glycerol plus
50 mM imidazole). The Ni–NTA resin was subsequently packed
into a 1 mL plastic column (Qiagen).
The unbound protein fraction was removed by washing the Ni–NTA
resin with 40 mL of washing buffer (50 mM Tris–HCl pH 7.4, 150 mM
NaCl, 0.1% sodium deoxycholate, 0.1% FOS-CHOLINE®-12, and 20% glyc-
erol plus 50 mM imidazole) while the bound protein was eluted adding
3 mL of elution buffer (50 mM Tris–HCl pH 7.4, 150 mM NaCl, 0.1% so-
diumdeoxycholate, 0.1% FOS-CHOLINE®-12, and 20% glycerol) contain-
ing 200 mM imidazole, and 3 mL of elution buffer containing 400 mM
imidazole; aliquots of 1 mL were collected. The bound protein was
also eluted with the elution buffers without any detergent. Fractions
containing protein were pooled and concentrated to 2.5 mL (from
5 mL) in a Vivaspin 30 K spin concentrator. To eliminate the imidazole,
the concentrated proteins were loaded into a PD-10 desalting column
(GE Healthcare) pre-equilibrated with equilibration buffer without im-
idazole, and eluted with 3.5 mL of the same buffer.
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The total protein concentration of each fraction was determined by
Bradford protein assay using bovine serum albumin (BSA) as standard
(Bio-Rad DC Protein assay). Cell lysates and membrane and cytosolic
fractions from each construct and culture medium from pPICZαA-
hPNPLA3-His6were diluted inNuPAGE® LDS Sample Buffer (Invitrogen)
plus 20 mM dithiothreitol (DTT), denatured at 95 °C for 10 min and
loaded on NuPAGE® 4–12% Bis-Tris Gel (Invitrogen). The run was per-
formed at 200 V for 35 min. For the SDS-PAGE analysis, gels were
stained using SimplyBlue Safe Stain (Invitrogen). In some experiments,
4% β-mercaptoethanol has been added as a reducing agent to the sam-
ple buffer.
For immunoblot analysis, gels were transferred to a nitrocellulose
membrane (Hybond ECL, GE Healthcare) at 100 V for 1 h. Nitrocellu-
lose membranes were incubated with anti-His (Clontech) or anti-
PNPLA3 (Sigma-Aldrich) antibody. Signals were detected using ECL
plus (GE Healthcare). To verify the purity of the recombinant pro-
teins, fractions containing PNPLA3 148I wild type and 148M mutant
were size-fractionated by SDS-PAGE and the bands of interest
excised and analyzed by mass spectrometry as previously described
[28].
2.6. Glycerolipid hydrolase activity assay
Substrate was prepared by combining 200 μM triolein, 1,3-diolein or
1-monooloieinwith 50 μMphosphatidylcholine and 25 μMradiolabeled
[3H]-triolein, [14C]-diolein or [14C]-monoolein. Lipids were dried under
nitrogen stream, resuspended in sonication buffer (170 mM K2HPO4
(pH 7.0) and 200 μM sodium taurocholate) and sonicated. Puriﬁed
PNPLA3 148I wild type or 148M mutant (0.5–50 μg) was incubated
with 100 μL of substrate in a total reaction volume of 200 μL for
30 min at 37 °C. The reaction was stopped by adding 3.25 mL of metha-
nol:chloroform:heptane (10:9:7, v/v) plus 1 mL of 0.1 M potassium car-
bonate/0.1 M boric acid, pH 10.5. After centrifugation at 3000 g for
15 min, theupperwater phasewas collected and counted for radioactiv-
ity ([3H] or [14C]-oleic acid) by liquid scintillation counting. For the
triglyceride hydrolase activity assay, experiments were also repeated
using increasing amounts of substrate and the results were ﬁtted to
the Michaelis–Menten kinetic curves to determine the Vmax and Km
values. Triglyceride hydrolase activity assay was also tested in the ab-
sence of detergents in the elution buffer (see Large-scale solubilization
and puriﬁcation of PNPLA3 148I wild type and 148M mutant paragraph)
and at different pH conditions (6.4, 6.8, 7.4 and 8.0).
2.7. Lysophosphatidic acid acyl transferase activity assay
Substrate was prepared by combining 200 μM oleoyl-L-a-
lysophosphatidic acid, 60 μM oleoyl-CoA and 20 μM [14C]-oleoyl-CoA
in 50 mM Tris–HCl buffer (pH 7.5). Puriﬁed PNPLA3 148I wild type or
148M mutant (0.5–50 μg) was incubated with 50 μL of substrate in a
total reaction volume of 100 μL for 30 min at 37 °C. The reaction was
stopped by adding 1.2 mL of chloroform:methanol (2:1 v/v) and
400 μL of acidiﬁed water (2% orthophosphoric acid). After centrifuga-
tion at 3000 g for 15 min, the upper water phase was discarded and
the lower organic phasewas collected and dried under nitrogen stream.
Lipids were reconstituted in 80 μL of chloroform and separated by thin
layer chromatography on a silica gel plate. Bands corresponding to
phosphatidic acid were visualized by iodine vapor staining, cut and
counted for radioactivity by liquid scintillation counting.
2.8. Thioesterase activity assay
Cold oleoyl-CoA (80 μM) and radiolabeled [14C]-oleoyl-CoA (20 μM)
were dried under nitrogen stream and resuspended in Tris–Cl (10 mM,
pH 7.4). The substrate was incubated with 50 μg of puriﬁed 148I or148 M PNPLA3 at 37 °C for 20 min. Lipids were extracted in
chlorophorm/methanol (2:1) plus 0.1 M potassium carbonate/0.1 M
boric acid solution and resolved by thin layer chromatography using
chloroform/methanol/ammonium hydroxide (65:25:5) as mobile
phase. Radioactivity was counted.3. Results
3.1. Puriﬁcation of human PNPLA3
To determine the optimal vector to use for production of PNPLA3,we
cloned the cDNAencoding PNPLA3 148Iwild type into the P. Pastoris ex-
pression vectors pPICZB (for intracellular protein production) and
pPICZαA (for secreted protein production). The constructs were linear-
ized and transformed to the P. pastoriswild type strain X-33. After high-
zeocin screening, we selected three of the best growing clones for each
construct and analyzed protein production by immunoblot. P. pastoris
cells transformed with either pPICZB-His6-hPNPLA3 or pPICZB-
hPNPLA3-His6 were positive for protein production and PNPLA3 local-
ized to the yeast membrane at the expected molecular weight (data
not shown). The highest protein production was observed with
pPICZB-hPNPLA3-His6. By contrast, PNPLA3 was not detected in the
cell culture medium fractions from P. pastoris cells transformed with
pPICZαA-hPNPLA3-His6 (data not shown).
Because of the successful production of PNPLA3 148I wild type
in P. pastoris cells transformed with pPICZB-hPNPLA3-His6, we
cloned the PNPLA3 148M mutant cDNA as a fusion with a C-
terminal His6-tag into the pPICZB vector, resulting in pPICZB-
hPNPLA3-148M-His6.
We chose the clones with the highest protein production (pPICZB-
hPNPLA3-His6 and pPICZB-hPNPLA3-I148M-His6) for large-scale pro-
duction in a 3 L fermentor. X-33/hPNPLA3 and X-33/hPNPLA3-I148M
were grown under tightly controlled conditions resulting in a substan-
tial increase in the total cellmass and in a total of 400 g ﬁnalwetweight.
We obtained membrane fractions by centrifugation and conﬁrmed the
presence of PNPLA3 148I wild type and 148M mutant by SDS-PAGE
and immunoblot (Fig. 1A and B, lanes 1 and 3).
The proteins were then solubilized and puriﬁed by Ni–NTA agarose
afﬁnity chromatography, resulting in highly pure samples (Fig. 2A and
B). PNPLA3 148I wild type and 148M mutant migrated predominantly
as one large monomeric band of the expected molecular size
(~55 kDa). A weaker band was also detected at higher molecular
weight (~130 kDa). Western blot analysis (Fig. 1B, Supplementary
Figs. 1 and 2) and mass spectrometry (Table 1) revealed the 130 kDa
band being a PNPLA3 oligomer. Only peptides containing the hPNPLA3
sequence were recognized after trypsin treatment of the monomer
(~55 kDa) and oligomer (~130 kDa) bands. The additional band corre-
sponding to the oligomeric form of PNPLA3 was present in E2–E4 frac-
tions and it was not detectable by Coomassie staining in E5–E6
fractions of stained gel (Fig. 2A and B). After blotting the membranes
of all fractions by using both anti-His and anti-PNPLA3 antibodies, the
oligomeric formwas visible in all fractions from E2 to E6 (Supplementa-
ry Figs. 1 and 2). This suggests that Coomassie stainingwas not sensitive
enough to visualize the bands in E5–E6 fractions due to lowprotein con-
centration. To further conﬁrm that the higher molecular weight band
was a PNPLA3 complex, we size-fractionated the protein on an SDS-
PAGE after adding 2% β-mercaptoethanol incubating at 95 °C for
5 min (Supplementary Fig. 3). We detected a single band at approxi-
mately 55 kDa after western blot using anti-human PNPLA3 antibody.
This ﬁnding is consistent with the band at 130 kDa being a dimer or a
trimer of the ADPN protein. By comparison with the SimplyBlue-
stained gel (Fig. 1A), we estimated the protein purity after Ni-
puriﬁcation and desalting to be N90%.We estimated the yield of puriﬁed
PNPLA3 148I wild type and I148M mutant to be 6 mg per liter of cell
culture.
Fig. 1. Membrane localized and puriﬁed PNPLA3 148I wild type and 148M mutant.
(A) SimplyBlue-stained SDS-PAGE (4–12%) electrophoresis analysis of PNPLA3 148I wild
type and148Mmutant.M: proteinmarker; lane 1:membrane fraction from fermentor cul-
ture of P. pastoris producing PNPLA3 148I wild type (15 μg); lane 2: puriﬁed PNPLA3 148I
wild type (2 μg); lane3:membrane fraction from fermentor culture of P. pastorisproducing
PNPLA3 148Mmutant (15 μg); lane 4: puriﬁed PNPLA3 148Mmutant (2 μg). (B) Immuno-
blot using an anti-His antibody showing membrane localized and puriﬁed hPNPLA3 148I
wild type and 148Mmutant, respectively. Lane 1: membrane fraction from fermentor cul-
ture of P. pastoris producing PNPLA3 148I wild type (5 μg); lane 2: puriﬁed PNPLA3 148I
wild type (1 μg); lane3:membrane fraction from fermentor culture of P. pastorisproducing
PNPLA3 148Mmutant (5 μg); lane 4: puriﬁed PNPLA3 148M mutant (1 μg). Puriﬁed 148I
wild type and 148M mutant PNPLA3 (lane 2 and 4) were obtained after pooling together
6elution fractions after Ni–NTA afﬁnity chromatography (see Fig. 2).
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To test the triglyceride hydrolase activity of the PNPLA3 148I wild
type and 148M mutant, we incubated the puriﬁed proteins with
radiolabeled triolein and measured the release of radiolabeled oleic
acid in the water fraction.We used oleic acid as substrate based on pre-
vious data [17,19,20] showing that oleic acid is the ideal substrate forFig. 2. Ni-puriﬁcation of PNPLA3 148I wild type and 148M mutant. SimplyBlue-stained
SDS-PAGE (4–12%) showing the elution fractions after Ni–NTA afﬁnity chromatography
of (A) PNPLA3 148I wild type and (B) PNPLA3 148Mmutant. Elution fractions one to six
are shown.M: proteinmarker; E1–E3: collected fractions after elutionwith buffer contain-
ing 200 mM imidazole; E4–E6: collected fractions after elution with buffer containing
400 mM imidazole.PNPLA3 activity. We found a concentration-dependent increase of
oleic acid release after incubation with 148I wild type but not with
148Mmutant (Fig. 3A). The protein amount for each reactionwas mea-
sured by immunoblot (Fig. 3C). These data indicate that PNPLA3 148I
wild type has a triglyceride hydrolase activity and that the isoleucine
to methionine substitution at 148 of the PNPLA3 protein results in a
loss of function. To examine whether the detergent contained in the
eluting solutionwas reducing the observed triglyceride hydrolase activ-
ity of PNPLA3 we repeated the experiment by using an elution buffer
with and without detergent and we observed no differences in the pro-
tein enzymatic activity (Supplementary Fig. 4).We tested also the effect
of the mutation on the Km and Vmax and we found that the Km was re-
duced from 61.06 to 35.63 μM, while the Vmax was reduced from
14.73 to 1.56 nmol/mg/min (Table 2, Supplementary Fig. 5).
To examine the effect of pH on protein activity, we performed the
experiment using 4buffers with different pH conditions (6.4, 6.8, 7.4
and 8.0).We found that PNPLA3 148I protein shows the highest activity
at a pH range between 6.8 and 7.4 (Supplementary Fig. 6).
Next, we examined the wild type and mutant PNPLA3 activity on
dioleoylglycerol, monoleoylglycerol and oleoyl-CoA (Table 3). We
found the wild type protein having DAG hydrolase and thioesterase ac-
tivities, and the mutation resulting in a loss of function. We found no
MAG hydrolase activity.
To test the LPAAT activity of the PNPLA3 148I wild type and 148M
mutant, we incubated the puriﬁed proteins with radiolabeled oleoyl-
CoA and lysophosphatidic acid and measured the formation of
radiolabeled phosphatidic acid. We used the same molar concentration
of substrate as for the triglyceride hydrolase assay and observed a
concentration-dependent formation of phosphatidic acid after incuba-
tion with 148I wild type but not with 148M mutant (Fig. 3B, Supple-
mentary Fig. 7). However, the rate of LPAAT activity was considerably
lower than the rate of triglyceride hydrolase activity.
4. Discussion
In this study, we present a reliable protocol for the production of
human PNPLA3 148I wild type and 148M mutant in yeast cells. The
main ﬁndings of this manuscript are that: (1) puriﬁed PNPLA3 has pre-
dominantly triglyceride hydrolase activity with mild LPAAT activity;
and (2) the isoleucine to methionine substitution at position 148 of
PNPLA3 results in a loss of function of both these activities.
Yeast is a powerful system for the overproduction of eukaryotic pro-
teins since it is a well characterized eukaryotic cell that is easy to grow
and manipulate. Especially, the methylotrophic yeast P. pastoris has a
very strong promoter, the alcohol oxidase promoter, fromwhich the re-
combinant gene can be expressed and very high yield of protein product
can be achieved. In addition, P. pastoris is easy to grow to high cell den-
sities when grown under controlled conditions in fermentors providing
a lot of start material for subsequent puriﬁcation and characterization of
the target of interest [29]. Selecting a suitable host is commonly crucial
for high production of functional membrane proteins. Noteworthy,
P. pastoris has been high-lighted as one of the most efﬁcient hosts for
the production of eukaryotic membrane proteins [30].
We showed that both PNPLA3 148I wild type and 148M mutant
were highly enriched in the membrane fraction following expression
in yeast cells, consistent with previous observations of the PNPLA3
being tightly attached to membranes [17,18]. Localization of PNPLA3
to the P. pastorismembrane is an initial indication of a correctly folded
and functional protein. Furthermore, the activity of recombinant
PNPLA3 was retained after solubilization and puriﬁcation, indicating a
stabile ﬁnal protein.
Earlier studies to address the enzymatic function of PNPLA3 have
shown that the protein has both triglyceride hydrolase [19] and syn-
thase activities [20]. Here we used triolein as substrate and showed
that puriﬁed PNPLA3 148I wild type had triglyceride hydrolase activity.
This activity was not affected by pH condition changes. The overall
Table 1
Mass values and amino acid sequences obtained by mass spectrometry analysis of the tryptic peptides of recombinant hPNPLA3 wild type
(monomer and oligomer).
Peptide mass (Da) PNPLA3 sequence position Peptide sequence
841.42 241–247 GYLDAFR
885.41 334–341 DKGGYMSK
886.50 225–232 AFVPPDLK
902.51 233–240 VLGEICLR
941.55 342–349 ICNLLPIR
1126.58 199–209 STNFLHVDITK
1182.64 253–263 GICNRPQPGLK
1189.64 397–406 VLmcLLPASR
1275.65 28–38 CLSEHAPHLLR
1309.67 296–306 LEGDELLDHLR
1323.71 214–224 LcTGNLYLLSR
1335.68 324–335 LATALSEEMKDK
1436.70 121–133 VSDGENVLVSDFR
1450.78 101–113 cLPANVHQLISGK
1473.78 80–92 NIGIFHPSFNLSK
1695.82 164–179 YVDGGVSDNVPFIDAK
1836.93 462–479 VPAGAEGLSTFPSFSLEK
1955.05 307–323 LSILPWDESILDTLSPR
2004.96 180–196 TTITVSPFYGEYDIcPK
2505.32 350–371 IMSYVMLPcTLPVESAIAIVQR
2944.21 452–479 SSLNFFLGNKVPAGAEGLSTFPSFSLEK
3325.47 264–295 SSSEGMDPEVAmPSWANMSLDSSPESAALAVR
m: oxidation; c: propionamide.
Puriﬁed hPNPLA3 wild type protein was size-fractionated on a SDS-PAGE. Two bands of 50 and 130 kDa respectively were identiﬁed and analyzed by mass
spectrometry. The same procedure was performed for the hPNPLA3 mutant protein with virtually identical results (data not shown).
578 P. Pingitore et al. / Biochimica et Biophysica Acta 1841 (2014) 574–580PNPLA3 observed lipase activity may be considered low if compared to
hormone sensitive lipase (HSL) [31] but of a similar magnitude if com-
pared to ATGL/PNPLA2 [20,32] which belongs to the same protein fam-
ily. These differences may be due to an intrinsic low protein enzymatic
activity.When assessing the TAG hydrolase activity using protein eluted
without detergent we did not see any differences compared to
detergent-containing elution buffer.
In regard to different substrate hydrolase activities, we found the
148I wild type protein to be active on diolein and oleoyl-CoA as previ-
ously shown [19] but not on monolein.
We also observed a synthase (LPAAT) activity of PNPLA3 148I wild
type, albeit with amuch lower rate of activity than that of the hydrolase.Fig. 3. hPNPLA3 148Iwild type shows predominant triglyceride hydrolase activity andmild LPAA
puriﬁed PNPLA3148Iwild type or 148Mmutantwere incubatedwith radiolabeled triolein. Lipid
centrifugation by liquid scintillation counting. (B) The indicated amounts of puriﬁed PNPLA3 14
oleoyl-CoA. Lipids were extracted and newly synthetized phosphatidic acid were separated by t
mg is intended as the quantity of substrate used for the incubation with increasing amount of t
Protein amount for each reaction was measured by immunoblot (C).Although the presence of both triglyceride hydrolase and synthase ac-
tivities might at ﬁrst seem contradictory, it is perhaps not surprising
since enzymes are usually able to catalyze reactions in both directions
[33]. Furthermore, the presence of both activities may be interpreted
as a sign of good quality and proper functioning of the protein.
Conﬂicting results have also been reported regarding the effect of
the I148M substitution on PNPLA3 [19,20]. Here we showed that the
I148M substitution resulted in a loss of both hydrolase and LPAAT activ-
ities of our puriﬁed protein. This is consistentwith the absence of chang-
es in the intracellular lipid content in cells overexpressing the mutant
148M protein [17]. In particular, the 148Mmutation induced a 10-fold
reduction of the Vmax and a 2-fold reduction in the Km. These valuesT activity and the I148Mmutation induces a loss of function. (A) The indicated amounts of
swere extracted and released radiolabeled oleic acidwasmeasured in thewater phase after
8I wild type or 148Mmutant were incubated with lysophosphatidic acid and radiolabeled
hin layer chromatography andmeasured by liquid scintillation counting. In panels A and B
he puriﬁed protein. Results are shown as mean of 3experiments +/− standard deviation.
Table 2
Km and Vmax of 148I and 148M PNPLA3 for trioleoylglycerol.
Substrate 148I 148M
Vmax Km Vmax Km
(nmol/mg/min) μM (nmol/mg/min) μM
TAG 14.73 61.06 1.56 35.63
PNPLA3 148I and 148 M puriﬁed proteins were incubated with increasing concentrations
of radiolabeled trioleoylglycerol. Lipids were extracted and resolved by thin layer
chromatography. Released oleic acid was measured by scintillation counting. Values
were ﬁtted to Michaelis–Menten kinetics curves to determine Vmax and Km values.
579P. Pingitore et al. / Biochimica et Biophysica Acta 1841 (2014) 574–580are consistent with previously reported data [19]. The I148M substitu-
tion also induced a complete loss of thioesterase activity, whereas
only a modest reduction in this activity was previously reported [19].
It is interesting to note that our observations of a predominant triglycer-
ide hydrolase activity of PNPLA3 148I and loss of function with the
I148M substitution are in agreement with an earlier study in which
PNPLA3 was puriﬁed in another eukaryote, namely insect cells [19].
Conversely, data from protein puriﬁed in a prokaryote (i.e. E. coli)
show a predominant synthase activity and the I148M mutation being
a gain of function [20]. This discrepancy may be due to intrinsic differ-
ences in the system used (prokaryote vs. eukaryote cells) including
the translation rate, the translocon, and the membrane lipid composi-
tion. A limitation of this study is that detergent was used to extract
the protein from the membrane fraction and this may reduce the enzy-
matic protein activity.
In conclusion, we have shown that puriﬁed PNPLA3 148I wild type
protein has a lipase activity and that the I148M substitution causes a
loss of function in this activity. Understanding the PNPLA3 enzymatic
function and the effect of the 148M substitution represents the ﬁrst
step to understand the molecular mechanism underlying the well
established genetic association with the entire spectrum of chronic
liver disease.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbalip.2013.12.006.
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148I 148M P value
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MAG hydrolase activity (nmol/mg/min) 0.14 ± 0.01 0.11 ± 0.02 0.12
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dioleoylglycerol,monoleoylglycerol and oleoyl-coenzymeA. Lipidswere extracted and re-
solved by thin layer chromatography. Released oleic acid was measured by scintillation
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